Simon J. Draper

This paper designs de novo minibinders that inhibit blood-stage malaria replication with nanomolar potency by targeting the RH5-basigin interaction.

The paper identifies synergistic antibody interactions against the malaria protein RIPR, showing how combinations of antibodies targeting specific domains inhibit parasite invasion.

The paper identifies two broadly neutralizing antibodies against Ebolavirus glycoprotein and shows that one enhances the neutralization breadth and potency of other antibodies.

The paper identifies synergistic non-neutralizing antibodies against PfRH5 that enhance malaria parasite growth inhibition when combined with neutralizing antibodies.

This study evaluates the cross-species neutralization potential of monoclonal antibodies against PfCyRPA and PfRIPR against P. knowlesi, finding minimal inhibition despite partial epitope conservation.

This paper designs a malaria vaccine immunogen using structure-guided methods to present a single epitope from PfRH5, showing improved antibody response in rats compared to PfRH5 alone.

The paper identifies potent neutralizing antibodies against the malaria antigen RH5 from natural infection, showing they target similar epitopes as vaccine-induced antibodies.

The paper characterizes human antibodies against PfRH5, identifies key features of potent inhibitors, and demonstrates their prophylactic potential against malaria.

This paper develops a stabilized RH5 VLP vaccine that induces improved anti-malarial antibodies compared to a soluble protein vaccine in preclinical studies.

This study designs an improved PvDBP-based immunogen using structure-guided methods to enhance its stability and antibody response against Plasmodium vivax.

This paper develops a combination malaria vaccine targeting the RCR-complex by fusing epitopes from RIPR to CyRPA, improving in vitro growth inhibition compared to RH5.1 alone.

This study evaluates the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development, finding significant assay-to-assay variation in %GIA and GIA50.